38. スティーヴンス・ジョンソン症候群 [臨床試験数:10,薬物数:14(DrugBank:8),標的遺伝子数:9,標的パスウェイ数:92]
Searched query = "Stevens Johnson syndrome", "Mucocutaneous ocular syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02987257 | December 2020 | 2 September 2019 | Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis | Phase III Randomized Trial of the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Comparing Supportive Care, Cyclosporine, and Biologic Therapy in Adults | Stevens-Johnson Syndrome;Toxic Epidermal Necrolyses | Drug: cyclosporin A;Drug: Etanercept 50 MG Solution for Injection;Drug: Placebos | Vanderbilt University Medical Center | University of Ottawa;University of Toronto;Loyola University;University of South Florida;University of Texas | Not recruiting | 18 Years | N/A | All | 267 | Phase 3 | United States |
2 | NCT03585946 | September 1, 2018 | 16 July 2018 | Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis | A Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis | Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis;Drug Reaction | Drug: Site specific standard of care comparison | Massachusetts General Hospital | Not recruiting | 18 Years | N/A | All | 750 | N/A | ||
3 | JPRN-jRCTs061180044 | 01/06/2017 | 22 July 2019 | Multicenter Open-trial of Steroid pulse therapy for SJS/TEN | Multicenter Open-trial of Steroid pulse therapy for SJS/TEN - MOSST Study | Stevens-Johnson syndrome and Toxic epidermal necrolysis | 1. infusion of methylprednisolone at 500~1000 mg/d (0.9% N/S in 3 hour) for 3 consecutive days. 2. Oral predonisolone (0.5 mg/kg/d) was initiated on the day following the last dose of methylprednisolone, and prednisolone was subsequently tapered within 2 weeks. If the ocular involvement score is more than 2, dose of oral predonisolone (1 mg/kg/d) is recommended. | Eishin Morita | Recruiting | 20 age old | 90 age old | Both | 20 | Phase 2 | Taiwan;Germany | |
4 | NCT02126020 | November 2014 | 16 December 2017 | Topical Infliximab in Autoimmune Eyes With Keratoprosthesis | Topical Infliximab in Autoimmune Eyes With Keratoprosthesis | Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane Pemphigoid | Drug: topical infliximab | James Chodosh, MD, MPH | Massachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM) | Not recruiting | 18 Years | 80 Years | All | 0 | Phase 1/Phase 2 | United States;Canada |
5 | NCT02149732 | May 2014 | 2 May 2016 | Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation | An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients | Limbal Stem Cell Deficiency;Stevens-johnson Syndrome;Ocular Cicatricial Pemphigoid;Chemical Burn | Biological: cultivated oral mucosal epithelial sheet transplantation | Seoul National University Hospital | Ministry of Health & Welfare, Korea | Not recruiting | 16 Years | N/A | Both | Phase 1/Phase 2 | Korea, Republic of | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT01696500 | October 2012 | 19 February 2015 | Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. | NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. | Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis | Drug: Intravenous immunoglobulin | Nihon Pharmaceutical Co., Ltd | Not recruiting | 20 Years | N/A | Both | 10 | Phase 3 | Japan | |
7 | NCT01582880 | March 2012 | 4 November 2019 | Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis | The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis | Chemical Injuries;Unspecified Complication of Corneal Transplant;Autoimmune Diseases;Ocular Cicatricial Pemphigoid;Stevens Johnson Syndrome;Lupus Erythematosus, Systemic;Rheumatoid Arthritis;Other Autoimmune Diseases | Drug: Riboflavin | Joseph B. Ciolino, MD | Not recruiting | 18 Years | N/A | All | 1 | Phase 1/Phase 2 | United States | |
8 | NCT01256489 | December 2010 | 17 November 2015 | Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) | Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis | Stevens-Johnson Syndrome;Corneal Blindness | Drug: Infliximab | Massachusetts Eye and Ear Infirmary | Not recruiting | 18 Years | N/A | Both | 0 | Phase 1/Phase 2 | United States | |
9 | NCT02037347 | October 2010 | 19 October 2017 | Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis | Palifermin Treatment of Toxic Epidermal Necrolysis | Toxic Epidermal Necrolysis;Stevens-Johnson Syndrome | Drug: Palifermin | Brett King | Swedish Orphan Biovitrum | Not recruiting | 18 Years | N/A | All | 1 | Phase 1/Phase 2 | United States |
10 | NCT01488396 | February 2007 | 19 February 2015 | Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye | Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye | Stevens-Johnson Syndrome | Drug: 0.05%cyclosporin eye drop | Mahidol University | Not recruiting | 18 Years | N/A | Both | 31 | Phase 4 | Thailand |